Incidentally discovered tumors of the endocrine glands

Future Oncology

Volumn 3, Issue 4, 2007, Pages 463-474

  Vardanian, Andrew J ^a   Hines, O Joe ^a   Farrell, James J ^a   Yeh, Michael W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adrenal; Endocrine; Incidentaloma; Neuroendocrine; Pancreas; Thyroid

Indexed keywords

B RAF KINASE; CATECHOLAMINE; DEXAMETHASONE; FLUORODEOXYGLUCOSE; METADRENALIN; METOMIDATE C 11; MINICHROMOSOME MAINTENANCE PROTEIN; MINICHROMOSOME MAINTENANCE PROTEIN 5; MINICHROMOSOME MAINTENANCE PROTEIN 7; MOLECULAR MARKER; PROTEIN RAD9; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADRENAL INCIDENTALOMA; ADRENALECTOMY; ASPIRATION BIOPSY; CANCER GENETICS; CANCER SIZE; COMPUTER ASSISTED TOMOGRAPHY; DEXAMETHASONE SUPPRESSION TEST; DIAGNOSTIC ACCURACY; ECHOGRAPHY; ENDOCRINE TUMOR; ENDOSCOPIC ECHOGRAPHY; GENE MUTATION; HUMAN; IMAGE ANALYSIS; INCIDENTAL FINDING; INCIDENTALOMA; LOW DRUG DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS RESECTION; PANCREAS TUMOR; PANCREATIC INCIDENTALOMA; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; SUBTOTAL THYROIDECTOMY; THYROID INCIDENTALOMA; TREATMENT INDICATION;

ADRENAL GLAND NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; ENDOCRINE GLAND NEOPLASMS; HUMANS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 34547912189     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.4.463     Document Type: Review

References (83)

1. Green D: Incidental findings computed tomography of the thorax. Semin. Ultrasound CT MR 26(1), 14-19 (2005).
2. Green DE, Woodward PJ: The management of indeterminate incidental findings detected at abdominal CT. Semin. Ultrasound CT MR 26(1), 2-13 (2005).
3. Burguera B, Gharib H: Thyroid incidentalomas. Prevalence, diagnosis, significance and management. Endocrinol. Metab. Clin. North Am. 29(1), 187-203 (2000).
4. Tan GH, Gharib H: Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann. Intern. Med. 126(3), 226-231 (1997).
5. Ross DS: Nonpalpable thyroid nodules - managing an epidemic. J. Clin. Endocrinol. Metab. 87(5), 1938-1940 (2002).
6. Mazzaferri EL: Managing small thyroid cancers. JAMA 295(18), 2179-2182 (2006).
7. Wang C, Crapo LM: The epidemiology of thyroid disease and implications for screening. Endocrinol. Metab. Clin. North Am. 26(1), 189-218 (1997).
8. Harach HR, Franssila KO, Wasenius VM: Occult papillary carcinoma of the thyroid. A 'normal' finding in Finland. A systematic autopsy study. Cancer 56(3), 531-538 (1985).
9. Arem R, Padayatty SJ, Saliby AH, Sherman SI: Thyroid microcarcinoma: prevalence, prognosis, and management. Endocr. Prast. 5(3), 148-156 (1999).
10. Barbaro D, Simi U, Meucci G, Lapi P, Orsini P, Pasquini C: Thyroid Papillary cancers: microcarcinoma and carcinoma, incidental cancers and non-incidental cancers - are they different diseases? Clin. Endocrinol. (Oxford) 63(5), 577-581 (2005).
11. Steele SR, Martin MJ, Mullenix PS, Azarow KS, Andersen CA: The significance of incidental thyroid abnormalities identified during carotid duplex ultrasonography. Arch. Surg. 140(10), 981-985 (2005).
12. Moosa M, Mazzaferri EL: Outcome of differentiated thyroid cancer diagnosed in pregnant women. J. Clin. Endocrinol. Metab. 82(9), 2862-2866 (1997).
13. Ito Y, Tomoda C, Uruno T et al.: Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World. J. Surg. 28(5), 498-501 (2004).
14. Wada N, Duh QY, Sugino K et al.: Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann. Surg. 237(3), 3991-407 (2003).
15. Machens A, Holzhausen HJ, Dralle H: The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 103(11), 2269-2273 (2005).
16. Lo CY, Chan WF, Lang BH, Lam KY, Wan KY: Papillary Microcarcinoma: is there any difference between clinically overt and occult tumors? World J. Surg. (2006).
17. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Heerden JA, Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 112(6), 1139-1146; discussion 1146-1137 (1992).
18. Papini E, Guglielmi P, Bianchini A et al.: Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J. Clin. Endocrinol. Metab. 87(5), (i941)-1946 (2002).
19. Kang HW, No JH, Chung JH et al.: Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid. 14(1), 29-33 (2004).
20. Kim EK, Park CS, Chung WY et at.: New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am. J. Roentgenol. 178(3), 687-691 (2002).
21. Chung WY, Chang HS, Kim EK, Park CS: Utrasonographic mass screening for thyroid carcinoma: a study in women scheduled to undergo a breast examination. Surg. Today 31(9), 763-767 (2001).
22. Davies I, Welch HG: Increasing incidence of thyroid cancer in the United States - 2002. JAMA 295(18), 2164-2167 (2006).
23. Yeh MW, Demircan O, Ituatte P, Clark OH: False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma. Thyroid. 14(3), 207-215 (2004).
24. Cooper DS, Doherty GM, Haugen BR et al.: Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16(2), 109-142 (2006).
25. Ell PJ: The contribution of PET/CT to improved patient management. Br. J. Radiol. 79(937), 32-36 (2006).
26. Cohen MS, Arslan N, Dehdashti F et al.: Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 130(6), 941-946 (2001).
27. Kang KW, Kim SK, King HS et al.: Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J. Clin. Endocrinol. Metab. 88(9), 4100-4104 (2003).
28. Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK: 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 115(6), 1074-1078 (2005).
29. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W: Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J. Nucl. Med. 37(9), 1468-1472 (1996).
30. Grunwald F, Kalicke T, Feine U et al.: Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur. J. Nucl. Med. 26(12), 1547-1552 (1999).
31. Wang W, Larson SM, Fazzari M et al.: Prognostic value of 18F fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J. Clin. Endrocrinol. Metab. 85(3), 1107-1113 (2000).
32. Adler LP, Bloom AD: Positron emission tomography of thyroid masses. Thyroid. 3(3), 195-200 (1993).
33. Bloom AD, Adler LP, Shuck JM: Determination of malignancy of thyroid nodules with positron mission tomography Surgery 114(4), 728-734; discussion 734-725 (1993).
34. Ishimori T, Patel PV, Wahl RL: Detection of unexpected additional primary malignancies with PET/CT: J. Nucl. Med. 46(5), 752-757 (2005).
35. Ramos CD, Chisin R, Yeung HW, Larson SM, Macapinlac HA: Incidental focal thyroid uptake on FDG positron emission tomographic scans may represent a second primary tumor. Clin. Nucl. Med. 26(3), 193-197 (2001).
36. Van den Bruel A, Maes A, De Potter T et al.: Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J. Clin. Endrocrinol. Metab. 87(4), 1517-1520 (2002).
37. Hooft L, van der Veldt AA, van Diest PJ et al.: 18F fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase i expression in the primary tumor. J. Clin. Endrocrinol. Metab. 90(1), 328-334 (2005).
38. Libby DM, Smith JP, Altorki NK, Pasmantier MW, Yankelevitz D, Henschke CI: Managing the small pulmonary nodule discovered by CT: Chest 125(4). 1522-1529 (2004).
39. Youserm DM, Huang T, Loevner LA, Langlotz CP: Clinical and economic impact of incidental thyroid lesions found with CT and MR. AJNR Am. J. Neurorodiol. 18 (8), 1423-4428 (1997).
40. Liebeskind A, Sikora AG, Komisar A, Slavit D, Fried K: Rates of malignancy in incidentally discovered thyroid nodules evaluated with sonography and fine-needle aspiration. J. Ultrasound Med. 24(5), 629-634 (2005).
41. Xing M: BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12(2), 245-262 (2005).
42. Namba H, Nakashima M, Hayashi T et al.: Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endrocrinol. Metab. 88(9), 4393-4397 (2003).
43. Nikiforova MN, Kimura ET, Gandhi M et al.: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endrocrinol. Metab. 88(11), 5399-5404 (2003).
44. Xing M, Westra WH, Tufano RP et al.: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endrocrinol. Metab. 90(12). 6373-6379 (2005).
45. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A: ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. Ann. Surg. 242(3), 353-361; discussion 361-353 (2005).
46. Kebebew E, Peng M, Reiff E, McMillan A: Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer. 106(12), 2592-2597 (2006).
47. Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A: Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms. World J. Surg. 30(5), 767-774 (2006).
48. Rosen J, He M, Umbricht C et al.: A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. Surgery 139(6), 1050-1056; discussion 1056-1057 (2005).
49. He H, Jazdzewski K, Li W et al.: The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl. Acad. Sci. USA 102(52), 19075-19080 (2005).
50. Pallante P, Visone R, Ferracin M et al.: MicroRNA deregulation in human thyroid papillary carcinomas. Endocr. Relat. Cancer 13(2), 497-508 (2006).
51. Weber F, Teresi RE, Broelch CE, Frilling A, Eng C: A limited set of human microRNA is deregulated in follicular thyroid carcinoma. J. Clin. Endrocrinol. Metab. 91(9), 3584-3591 (2006).
52. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B: Incidentally discovered adrenal masses. Endocr. Rev. 16(4), 460-484 (1995).
53. Grumbach MM, Biller BM, Braunstein GD et al.: Management of the clinically inapparent adrenal mass ('incidentaloma). Ann. Interm. Med. 138(5), 424-429.
54. Mansmann G, Lau J, Balk E, Rothberg M. Miyachi Y, Bornstein SR: The clinically inapparent adrenal mass: update in diagnosis and management. Endocr. Rev. 25(2), 309-340 (2004).
55. Lal G, Duh QY: Lapatroscopic adrenalectomy - indications and technique. Surg. Oncol. 12(2),105--123 (2003).
56. Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E: Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J. Am. Coll. Surg. 202(3), 423-430 (2006).
57. Cook DM: Adrenal mass. Endrocrinol. Metab. Clin. North Am. 26(4), 829-852 (1997).
58. Bovio S, Cataldi A. Reimondo G et al.: Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J. Endocrinol. Invest. 29(4), 298-302 (2006).
59. Freitas JE: Adrenal cortical and medullary imaging. Semin. Nucl. Med. 25(3), 235-230 (1995).
60. Sahdev A, Reznek RH: Imaging evaluation of the non-functioning indeterminate adrenal mass. Trends Endocrinol. Metab. 15(6), 271-276 (2004).
61. Kouriefs C, Mokbel Y, Choy C: Is MRI more accurate than CT in estimating the real size of adrenal tumours? Eur. J. Surg. Oncol. 27(5), 487-490 (2001).
62. Lau H, Lo CY, Lam KY: Surgical implications of underestimation of adrenal tumour size by computed tomography. Br. J. Surg. 86(3), 385-387 (1999).
63. Cerfolio RJ, Vaughan ED Jr, Brennan TG Jr, Hirvela ER: Accuracy of computed tomography in predicting adrenal tumor size. Surg. Gynecol. Obstet. 176(4), 307-309 (1993).
64. Sturgeon C, Kebebew E: Laparoscopic adrenalectomy for malignancy. Surg. Clin. North Am. 84(3), 755-774 (2004).
65. Dackiw AP, Lee JE, Gagel RF, Evans DB: Adrenal cortical carcinoma. World J. Surg. 25(7), 914-926 (2001).
66. Yeh MW, Duh QY: The adrenal glands. In: Sabiston Textbook of Surgery (18th Edition). Townsend CM, Beauchamp RD, Evers BM, Mattor KL (Eds). (2007) (In Press).
67. Aubert S, Wacrenier A, Leroy X et at.: Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J. Surg. Pathol. 26(12), 1612-1619 (2002).
68. Thompson LD: Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms. a clinicopathologic and immunophenotypic study of 100 cases. Am. J. Surg. Pathol. 26(5), 551-566 (2002).
69. Yun M, Kim T, Alnafisi N, Lacorte L, Jang S, Alavi A: 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI: J. Nucl. Med. 42(12), 1795-1799 (2001).
70. Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M: The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. J. Nucl. Med. 42(6), 884-892 (2001).
71. Maurea S, Mainolfi C, Bazzicalupo L et al.: Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR Am. J. Roentgenol. 173(1), 25-29 (1999).
72. Rufini V, Calcagni ML, Baum RP: Imaging of neuroendocrine tumors. Semin. Nucl. Med. 36(3), 228-247 (2006).
73. Minn H, Salonen A, Friberg J et al.: Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG: J. Nucl. Med. 45(6), 972-979 (2004).
74. Bergstrom M, Juhlin C, Bonaseta TA et al.: PET imaging of adrenal cortical tumors with the 11β-hydroxylase tracer 11C-metomidate. J. Nucl. Med. 41(2), 275-282 (2000).
75. Khan TS, Sundin A, Juhlin C, Langstrom B, Bergstrom M, Eriksson B: 11C-metomidate PET imaging of adrenocortical cancer. Eur. J. Nucl. Med. Mol. Imaging 30(3), 403-410 (2003).
76. Fitzgerald TL, Smith AJ, Ryan M et al.: Surgical treatment of incidentally identified pancreatic masses. Can. J. Surg. 46(6), 413-418 (2003).
77. Kazanjian KK, Reber HA, Hines OJ: Resection of pancreatic neuroendocrine tumors: result of 70 cases. Arch. Surg. 141(8), 765-769; discussion 769-770 (2006).
78. Norton JA: Surgery for primary pancreatic neuroendocrine tumors. J. Gastrointest. Surg. 10(3), 327-331 (2006).
79. Volmar KE, Vollmer RT, Jowell PS, Nelson RC, Xie HB: Pancreatic FNA in cases: a comparison of imaging modalities. Gastrointest. Endosc. 61(7), 854-861 (2005).
80. Wittmann J, Kocjan G, Sqouros SN, Deheragoda M, Pereira, SP: Endoscopic ultrasound-guided tissue sampling by combined fine needle aspiration and trucur needle biopsy: a pospective study. Cytopathology 17(1), 27-33 (2006).
81. Arnold R, Rinke A, Schmidt C, Hofbauer L: Endocrine tumours of the gastrointestinal tract: Chemotherapy. Best Pract. Res. Clin. Gastroenterol. 19(4), 649-656 (2005).
82. Saunders BD, Wainess RM, Dimick JB, Upchurch GR, Doherty GM, Gauger PG: Trends in utilization of adrenalectomy in the United States: have indications changed? World J. Surg. 28(11), 1169-1175 (2004).
83. Vagefi PA, Razo O, Deshpande V et al.: Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1997-2005. Arch. Surg. 142(4), 347-354 (2007).